Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 356 of 1,261
  1. WO 2021053040

    MÉTHODES DE RADIOMARQUAGE D'ANTAGONISTES DE GRPR ET LEURS KITS

    ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] · Granted Mar 25, 2021 · Expires Mar 20, 2041

    granted
  2. WO 2021052960

    COMPOSITION RADIOPHARMACEUTIQUE CONCENTRÉE, STABLE

    ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] · Granted Mar 25, 2021 · Expires Mar 20, 2041

    granted
  3. US 10953209

    Treating tumors using TTFields combined with a PARP inhibitor

    The Board of Regents of the University of Texas System · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  4. US 10954529

    Minimal volume reprogramming of mononuclear cells

    Fate Therapeutics, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  5. US 10954498

    Modified cascade ribonucleoproteins and uses thereof

    Caribou Biosciences, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  6. US 10954259

    Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

    Compass Pathfinder Limited · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  7. US 10954198

    Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases

    United Kingdom Research and Innovation · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  8. US 10953047

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  9. US 10953040

    Methods of treating bacterial infections with penam β-lactam antibiotics and branched poly(ethylenimine)

    The Board of Regents of the University of Oklahoma · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  10. US 10952996

    ALK5 inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  11. US 10953026

    N-acetyl mannosammine as a therapeutic agent

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  12. US 10952978

    Hepatitis B antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  13. US 10953110

    Dual emissive metal nanoparticles as ratiometric pH indicators

    The Board of Regents of the University of Texas System · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  14. US 10954530

    Retroviral and lentiviral vectors

    AUTOLUS LIMITED · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  15. US 10954516

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  16. US 10954501

    Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use

    Catalyst Biosciences, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  17. US 10954492

    Processes for production and purification of nucleic acid-containing compositions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  18. US 10954304

    Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy

    The Regents of the University of California · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  19. US 10954295

    Correctly folded etanercept in high purity and excellent yield

    Coherus BioSciences, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  20. US 10954294

    Correctly folded etanercept in high purity and excellent yield

    Coherus BioSciences, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  21. US 10954291

    Monoclonal antibodies that specifically bind to matrilin-3 and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  22. US 10954289

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  23. US 10954293

    Correctly folded etanercept in high purity and excellent yield

    Coherus BioSciences, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  24. US 10954287

    Ras binding peptides and methods of use

    RA PHARMACEUTICALS, INC. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.